Genenta Acquires Majority Stake in Sophia High Tech

H.I.G. Capital Acquires Majority Stake in Naturalia Tantum S.p.A.

July 23, 2024

Consumer Products

H.I.G. Capital has acquired a majority stake in Naturalia Tantum S.p.A., a Milan-based developer, manufacturer and distributor of natural and organic beauty & personal care products. The investment, made in partnership with the company’s current management, is intended to accelerate Naturalia Tantum’s organic and inorganic growth domestically and internationally.

Softek Acquires Gentech (H2 FinTech)

July 12, 2022

Software

Softek, a provider of capital and credit management solutions, has acquired Gentech (H2 FinTech), a technology and software services firm serving broker-dealers and registered investment advisors (RIAs). The acquisition adds Gentech's compliance, sales supervision, commission compensation and portfolio management platform and technical development team to Softek, expanding its capabilities and reach into the RIA/independent broker-dealer market.

GenNx360 Capital Partners Acquires Majority Stake in Tensentric

March 18, 2022

Medical Devices

GenNx360 Capital Partners has made a majority investment in Tensentric, a Boulder-based provider of design, engineering, prototyping and assembly services for medical technology, IVD and life-sciences companies. The investment will support Tensentric's next phase of growth and enable the company to scale its services capabilities through organic and inorganic initiatives.

Montagu Acquires Majority Stake in HTL Biotechnology

February 28, 2022

Pharmaceuticals

Montagu, a leading private equity firm, has acquired a majority stake in HTL (HTL Biotechnology) from Bridgepoint, with minority shareholders Naxicap and Téthys Invest retaining their holdings. Montagu will support HTL's international expansion, R&D and premium product positioning and has appointed Paul Navarre as Chairman to help drive the company's next growth phase.

HiberCell Acquires Genuity Science, Inc.

August 16, 2021

Biotechnology

HiberCell, a clinical-stage oncology company, acquired Genuity Science, a genomics and multi‑omic analytics company with an advanced AI/ML platform, to integrate next‑generation computational capabilities into its translational oncology efforts. The stock acquisition brings Genuity and its subsidiaries into HiberCell, provides approximately $100 million in cash and existing partnership earnouts, and is intended to accelerate HiberCell's clinical programs and expand its preclinical pipeline.

Summa Equity Acquires Majority Stake in Sengenics

October 14, 2020

Biotechnology

Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.